Verastem | VSTM - Selling And Administration Expenses


Verastem reported $12.28M in Selling and Administration Expenses for its fiscal quarter ending in September of 2024.





Selling And Administration Expenses Change Date
AbbVie USD 3.89B 325M Dec/2025
Alaunos Therapeutics USD 585K 84K Sep/2025
AstraZeneca USD 4.61B 4.46B Dec/2025
Curis USD 4.79M 100K Jun/2024
Cytokinetics USD 91.72M 67.02M Dec/2025
Gilead Sciences USD 1.78B 425M Dec/2025
Incyte USD 390.41M 61.33M Dec/2025
Laboratory Of America USD 538.6M 13.8M Dec/2025
Novartis USD 3.44B 128M Dec/2025
Pfizer USD 4.08B 894M Dec/2025
Roche Holding CHF 7.28B 3.99B Dec/2025
TG Therapeutics USD 50.73M 12.64M Dec/2025
Verastem USD 12.28M 2.06M Sep/2024